PLOS Global Public Health (Jan 2023)

Vaccination coverage and breakthrough infections of COVID-19 during the second wave among staff of selected medical institutions in India.

  • Manju Rahi,
  • Chander Prakash Yadav,
  • Sundus Shafat Ahmad,
  • Nitika,
  • Payal Das,
  • Shweta Sharma,
  • Rajendra Kumar Baharia,
  • Debdutta Bhattacharya,
  • Pradeep Deshmukh,
  • Amey Dhatrak,
  • Sandeep Dogra,
  • Alex Eapen,
  • Pawan Goel,
  • Nafis Faizi,
  • Siraj A Khan,
  • Sanjay Kumar Kochar,
  • Aditya Kochar,
  • Ashwani Kumar,
  • Anuj Mundra,
  • Rahul Narang,
  • Kanwar Narain,
  • Krishna Pandey,
  • Sanghamitra Pati,
  • Pankaja Raghav,
  • Ritesh Ranjha,
  • Salman Shah,
  • Kuldeep Singh,
  • Piyoosh Kumar Singh,
  • Raj Kumar Singh,
  • Vijesh Shreedhar Kuttiatt,
  • Ravinder Soni,
  • Uragayala Sreehari,
  • Sumit Malhotra,
  • Amit Sharma

DOI
https://doi.org/10.1371/journal.pgph.0000946
Journal volume & issue
Vol. 3, no. 4
p. e0000946

Abstract

Read online

India experienced the second wave of SARS-CoV-2 infection from April 3 to June 10, 2021. During the second wave, Delta variant B.1617.2 emerged as the predominant strain, spiking cases from 12.5 million to 29.3 million (cumulative) by the end of the surge in India. Vaccines against COVID-19 are a potent tool to control and end the pandemic in addition to other control measures. India rolled out its vaccination programme on January 16, 2021, initially with two vaccines that were given emergency authorization-Covaxin (BBV152) and Covishield (ChAdOx1 nCoV- 19). Vaccination was initially started for the elderly (60+) and front-line workers and then gradually opened to different age groups. The second wave hit when vaccination was picking up pace in India. There were instances of vaccinated people (fully and partially) getting infected, and reinfections were also reported. We undertook a survey of staff (front line health care workers and supporting) of 15 medical colleges and research institutes across India to assess the vaccination coverage, incidence of breakthrough infections, and reinfections among them from June 2 to July 10, 2021. A total of 1876 staff participated, and 1484 forms were selected for analysis after removing duplicates and erroneous entries (n = 392). We found that among the respondents at the time of response, 17.6% were unvaccinated, 19.8% were partially vaccinated (received the first dose), and 62.5% were fully vaccinated (received both doses). Incidence of breakthrough infections was 8.7% among the 801 individuals (70/801) tested at least 14 days after the 2nd dose of vaccine. Eight participants reported reinfection in the overall infected group and reinfection incidence rate was 5.1%. Out of (N = 349) infected individuals 243 (69.6%) were unvaccinated and 106 (30.3%) were vaccinated. Our findings reveal the protective effect of vaccination and its role as an essential tool in the struggle against this pandemic.